About beam therapeutics inc. - BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
BEAM At a Glance
Beam Therapeutics, Inc.
238 Main Street
Cambridge, Massachusetts 02142-1016
| Phone | 1-857-327-8775 | Revenue | 63.52M | |
| Industry | Biotechnology | Net Income | -376,742,000.00 | |
| Sector | Health Technology | Employees | 483 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BEAM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 32.138 |
| Price to Book Ratio | 2.828 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.435 |
| Enterprise Value to Sales | 21.286 |
| Total Debt to Enterprise Value | 0.119 |
BEAM Efficiency
| Revenue/Employee | 131,507.246 |
| Income Per Employee | -780,004.141 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.05 |
BEAM Liquidity
| Current Ratio | 4.823 |
| Quick Ratio | 4.823 |
| Cash Ratio | 4.673 |
BEAM Profitability
| Gross Margin | 65.482 |
| Operating Margin | -654.252 |
| Pretax Margin | -593.065 |
| Net Margin | -593.126 |
| Return on Assets | -29.392 |
| Return on Equity | -43.938 |
| Return on Total Capital | -42.095 |
| Return on Invested Capital | -37.251 |
BEAM Capital Structure
| Total Debt to Total Equity | 22.006 |
| Total Debt to Total Capital | 18.037 |
| Total Debt to Total Assets | 14.624 |
| Long-Term Debt to Equity | 20.17 |
| Long-Term Debt to Total Capital | 16.532 |